Price Chart

Profile

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
URL https://www.exactsciences.com
Investor Relations URL https://investor.exactsciences.com/investor-relations/default.aspx
HQ State/Province Wisconsin
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 21, 2025 (est.)
Last Earnings Release Nov. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
URL https://www.exactsciences.com
Investor Relations URL https://investor.exactsciences.com/investor-relations/default.aspx
HQ State/Province Wisconsin
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 21, 2025 (est.)
Last Earnings Release Nov. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A